Giant Bilateral Angiomyolipoma Associated with Tuberous Sclerosis of Bourneville: Exceptional Case and Therapeutic Dilemma

Benatta Mahmoud a*

a Oran 1 Ahmed Ben Bella - CHU Oran Algeria, Algeria.

Author’s contribution

The sole author designed, analyzed, interpreted and prepared the manuscript.

Article Information

DOI: 10.9734/AJRID/2021/v8i430244

Editor(s):
(1) Dr. Giuseppe Murdaca, University of Genoa, Italy.

Reviewers:
(1) Rushani Samarakoon, National Hospital of Sri Lanka, Sri Lanka.
(2) Ahmed Chyad Abbas AL-Barqawee, The Norwegian Directorate of health in Oslo, Norway.

Complete Peer review History: https://www.sdiarticle4.com/review-history/72959

ABSTRACT

Angiomyolipoma (AML) is a mesenchymal tumour composed of variable proportions of adipose tissue and vascular and smooth muscle elements. It can cause potentially life-threatening complications. This report aims to describe a bilateral angiomyolipoma associated with tuberous sclerosis of Bourneville; the second aim is to discuss the treatment modalities of this disease.

A 51-year-old woman with abdominal mass and characteristic triad: Epilepsy, mental retardation and skin lesions (adenoma) (Fig. 1), with no notion of hematuria or abdominal pain, abdominal ultrasonography and computed tomography showing bilateral renal masses of 28.4×17 cm on the left kidney and 22× 11.7 cm on the right, respectively (Fig. 2-3). Serum creatinine was 13.4g/l.

Body-scan imaging finds cardiac rhabdomyoma (Fig. 4) and brain calcifications (Fig. 5). The patient underwent surveillance with scan imaging every month, and at the last control, she was asymptomatic, serum creatinine was still normal. The management of giant bilateral AML is a complex and multifactorial decision. Patients can knowingly choose an active surveillance program, even with giant AML, but the economic situation and mental status can limit the therapeutic choice.

Keywords: Angiomyolipoma; tuberous-sclerosis; bourneville.

*Corresponding author: E-mail: benatta.mahmoud@gmail.com;
1. INTRODUCTION

Angiomyolipoma (AML) is a renal mesenchymal tumor composed of varying proportions of adipose tissue and vascular and smooth muscle elements. It can cause significant, potentially life-threatening complications. The first aim of this case report is to describe a bilateral angiomyolipoma associated with tuberous sclerosis of Bourneville (TSB), the second aim is to discuss the treatment modalities of this disease.

2. CASE PRESENTATION

A 51-year-old woman with an abdominal mass and a characteristic triad: epilepsy, mental retardation and skin lesions (adenoma) (Fig. 1), we found no evidence of hematuria or abdominal pain, she underwent ultrasonography and then computed tomography, which showed the presence of bilateral renal masses of 28.4×17 cm on the left kidney and 22× 11.7 cm on the right kidney (Fig. 2-3). Serum creatinine was: 13.4g/l.

The patient also underwent a whole body examination, which revealed cardiac rhabdomyomas (Fig. 4) and calcifications in the brain (Fig. 5). She underwent a surveillance regimen with monthly imaging, and at the last follow-up she was asymptomatic and serum creatinine was still normal. Treatment of giant bilateral AML is a complex and multifactorial decision. Patients may make a conscious decision to follow an active surveillance program, even in the case of giant AML, but economic situation and mental status may limit therapeutic choices.

Fig. 1. Caracteristic skin lesions of tuberous sclerosis de bourneville
Figs. 2 and 3. Abdominal scan showing giant bilateral angiomyolipoma

Fig. 4. Cardiac rhabdomyome
3. DISCUSSION

Angiomyolipomas represent 1% to 3% of solid renal tumors, with females predominance [1]. Bilateral and multiple localizations are observed in 50% to 80% of cases. To our knowledge, the volume has never been 28 cm in the published literature, and the maximum diameter has ranged from 2 to 15 cm [2].

TSB is a dominant autosomal affection with variable pénétrance. Unfortunately, detection of micro-aneurysms requires arteriography embolisation generate in

The association of bilateral bilateral and TSB is exceptional, we can say that in such a situation a dangerous risk of bleeding is possible, but the size alone is not sufficient to assess the risk of bleeding.

The importance of vascular and fatty contingencies and the presence of intra-tumoral microanomalies greater than 5 mm could also be risk factors.
6% of cases a "Post-embolization syndrome" with low back pain and fever that can be controlled with non steroidal anti-inflammatory treatment or short-term corticosteroid treatment-the reduction in diameter depends on the proportion of vascular and fat. Embolization can be repeated during surveillance [3].

Cryoablation, radiofrequency and angiogenesis inhibitors may be used. m TOR-inhibitors may also play a role.

Because of their potential adverse effects, mTOR inhibitors should be prescribed only by specialized teams and, when possible, in the context of clinical trials.

m TOR inhibitors should not be used as first-line therapy in the treatment of renal AMLs. Some authors recommend prophylactic treatment, particularly in large tumor.

AMLs that accumulate risk factors for bleeding (size 80 mm, predominant vascular contingencies, microaneurisms), if possible by embolization.

Patients in whom follow-up or access to emergency care may be inadequate [4].

4. CONCLUSION

Giant bilateral angiomyolipomas associated with tuberous sclerosis of Bourneville remain the exception.

Diagnosis is straightforward, assessment is mandatory to evaluate risk. Therapeutic options: Surgery, endovascular, endovascular, adapted to the situation.

The management of bilateral giant angiomyolipoma is complex, and the therapeutic decision depends on several tumor and patient factors.

DISCLAIMER

Some part of this manuscript was previously presented in the following conference.

Conference name: Uros Lyon · At: Lyon

Dates: January 2018; Location: Algeria; Web Link of the proceeding:

https://www.researchgate.net/publication/322603457_Giant_Bilateral_Angiomyolipoma_Associated_with_Tuberous_Sclerosis_of_Bourneville_Exceptional_Case_and_Therapeutic_Dilemma

CONSENT

As per international standard or university standard, patient’s consent has been collected and preserved by the authors.

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES


© 2021 Benatta Mahmoud; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle4.com/review-history/72959